Fallopian tube cancer metastatic – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 02 Jun 2026 04:10:50 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Fallopian tube cancer metastatic – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Mirvetuximab Soravtansine and Carboplatin for Patients with Recurrent Ovarian Cancer Eligible for Platinum-Based Chemotherapy https://clinicaltrials.eu/trial/study-on-mirvetuximab-soravtansine-and-carboplatin-for-patients-with-recurrent-ovarian-cancer-eligible-for-platinum-based-chemotherapy/ Wed, 29 Apr 2026 14:58:04 +0000 https://clinicaltrials.eu/trial/study-on-mirvetuximab-soravtansine-and-carboplatin-for-patients-with-recurrent-ovarian-cancer-eligible-for-platinum-based-chemotherapy/ This clinical trial is focused on studying the treatment of recurrent ovarian cancer, a type of cancer that returns after initial treatment. The study involves a new treatment called Mirvetuximab soravtansine, which is being tested in combination with a chemotherapy drug called Carboplatin. The purpose of the study is to evaluate the effectiveness and safety of this combination in patients whose cancer has a high level of a protein called folate receptor alpha and who are eligible for platinum-based chemotherapy.

Participants in the study will receive either the new treatment combination or a standard treatment, which may include drugs like Gemcitabine, Paclitaxel, Doxorubicin, Rucaparib, Olaparib, or Niraparib. Some participants may receive a placebo. The study will monitor the time it takes for the cancer to progress or for the patient to pass away, whichever happens first. This is known as progression-free survival. The study will also look at overall survival, which is the time from the start of the study until death from any cause, and the response rate, which measures how well the cancer responds to the treatment.

The trial will last for several years, and participants will be closely monitored throughout the study. The study aims to provide valuable information about the potential benefits and risks of using Mirvetuximab soravtansine with Carboplatin in treating recurrent ovarian cancer. This research could lead to new treatment options for patients with this type of cancer.

]]>